Amatuximab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | mesothelin |
| Identifiers | |
| CAS Number | 931402-35-6  |
| ATC code | none |
| Chemical data | |
| Formula | C6394H9870N1694O2024S46 |
| Molecular mass | 144.33 kg/mol (peptide) |
 (what is this?) (verify) |
|
Amatuximab is a chimeric monoclonal antibody designed for the treatment of cancer.[1]
Amatuximab was developed by Morphotek, Inc.
Amatuximab is also known as Anti-mesothelin monoclonal antibody MORAb-009. Amatuximab is an anti-mesothelin monoclonal antibody MORAb-009 binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing, and also called MORAb-009.[citation needed]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- Anti-mesothelin monoclonal antibody MORAb-009 entry in the public domain NCI Dictionary of Cancer Terms
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles with unsourced statements from October 2013
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
